Pear-Sandoz's conscious uncoupling. W. Virgina wants DTx.

Issue 024.

Get E&O weekly. | Subscribe | Digital health research from Brian Dolan.

Welcome to E&O.

Last week's newsletter had a 66 percent open rate, which, considering all the new enterprise subscribers, is A-OK by me. Here's what's happening this week:

The "bomb cyclone" of a Nor'Easter that hit the Boston-area Wednesday night slowed things down a little, but the only real casualty around here was one of the more promising branches I grafted to my apple tree this spring. Such are the trials and tribulations of backyard orcharding.
Fitbit continues its (probably quixotic) quest to transform its business into a behavior change company focused on helping people manage serious medical conditions before its low stock price gets it acquired. On-stage at Time's healthcare conference, CEO James Park announced a deal with the Bristol-Myers Squibb-Pfizer Alliance focused on atrial

Paying Subscribers Only

It's a good one, too.

This digital health research is for paying Exits & Outcomes subscribers only. Subscribe now to read this article, get the weekly newsletter, and receive unrestricted access to past and future research from the Exits & Outcomes archives. Smash the link above or below to subscribe yourself -- or head over to our pricing page to subscribe your team or your whole company!

Pear-Sandoz’s conscious uncoupling. W. Virgina wants DTx.

Welcome to E&O.

Paying Subscribers Only

Full access to E&O's research and newsletters.

Pear-Sandoz’s conscious uncoupling. W. Virgina wants DTx.

Welcome to E&O.

Paying Subscribers Only

Full access to E&O's research and newsletters.

New! E&O's free weekly newsletter.